Sandborn WJ, Danese S, Leszczyszyn J, Romatowski J, et al. Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study. Clin Gastroenterol Hepatol 2023 Jan 6:S1542-3565(23)00007.
PMID: 36623678